# Converting From Ropinirole Immediate Release (IR) To Ropinirole Controlled-Release for RLS (Restless Legs Syndrome)

> **NCT00256854** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 135 (actual)

## Conditions studied

- Restless Legs Syndrome
- Restless Legs Syndrome (RLS)

## Interventions

- **DRUG:** Ropinirole IR 1 mg
- **DRUG:** Ropinirole IR 2 mg
- **DRUG:** Ropinirole IR 1 mg Placebo
- **DRUG:** Ropinirole IR 2 mg Placebo
- **DRUG:** Ropinirole CR 2 mg
- **DRUG:** Ropinirole CR 3 mg
- **DRUG:** Ropinirole CR 2 mg Placebo
- **DRUG:** Ropinirole CR 3 mg Placebo

## Key facts

- **NCT ID:** NCT00256854
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-11-14
- **Primary completion:** 2006-09-21
- **Final completion:** 2006-09-21
- **Target enrollment:** 135 (ACTUAL)
- **Last updated:** 2019-03-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00256854

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00256854, "Converting From Ropinirole Immediate Release (IR) To Ropinirole Controlled-Release for RLS (Restless Legs Syndrome)". Retrieved via AI Analytics 2026-09-04 from https://api.ai-analytics.org/clinical/NCT00256854. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*